- Breast Cancer
- Cancer Control
- Diagnostics and Screening
- Gastrointestinal Oncology
- Genitourinary Cancers
- Geriatric Oncology
- Gynecological Oncology
- Head, Neck and Thyroid Cancers
- Hematological Malignancies
- Infection in Hematology
- Lung Cancer
- Neurological Oncology
- Patient Care
- Pediatric Oncology
- Platelets, Hemostasis and Thrombosis
- Red Blood Cells
- Supportive Oncology
The Clinical Pharmacology of Anastrozole
European Oncology & Haematology, 2011;7(2):106-108
AbstractAnastrozole is a potent non-steroidal aromatase inhibitor that selectively inhibits aromatase. It is the first aromatase inhibitor approved by the US Food and Drug Administration as an adjuvant hormonal therapy in early-stage breast cancer. With most patients needing to take anastrozole for two to five years, it is important for physicians to understand the clinical pharmacology of anastrozole. Anastrozole has excellent oral bioavailability and is widely distributed throughout the body. It is extensively metabolised by the liver, with a half-life of 40–50 hours. Anastrozole is primarily excreted through the faecal route. Steady-state concentrations are achieved after seven days of once-daily administration. The standard dosage of anastrozole is 1mg/day orally. No dose adjustments are necessary based on hepatic or renal dysfunction. No significant drug–drug interaction has been reported with anastrozole use. This article is to summarise the existing knowledge of the pharmacokinetics of anastrozole.
Keywords: Anastrozole, pharmacokinetics, aromatase inhibitor, breast carcinoma, oestrogen, post-menopausal
Disclosure: The authors have no conflicts of interest to declare.
Received: March 15, 2010 Accepted September 10, 2010 Citation European Oncology & Haematology, 2011;7(2):106-108
Correspondence: Ting Bao, 22 S Greene Street, Baltimore, MD 21201, US. E: firstname.lastname@example.org
Breast cancer is the most common cancer and the second most common cause of cancer death among women in the US.1 It is estimated that two-thirds of the invasive breast cancers will be hormone-receptor-positive and will require long-term adjuvant hormonal therapy.
Reducing the effect of oestrogen is the main aim of hormonal therapy in treating hormone-receptor-positive breast cancer. The effect of oestrogen is reduced in two ways – by blocking the oestrogen receptor or by inhibiting oestrogen biosynthesis. The mechanism of action of aromatase inhibitors (AIs) is to inhibit oestrogen biosynthesis. AIs have established their role in treating metastatic hormone-receptor-positive breast cancer in post-menopausal women through a number of clinical trials.2–5 In addition, multiple clinical trials have shown that AIs have superior efficacy compared with tamoxifen as an adjuvant hormonal therapy in post-menopausal women with hormone-receptor-positive breast cancer.6–11 AIs are therefore the recommended first-line adjuvant hormonal therapy in post-menopausal women with hormone-receptor-positive breast cancer, either as monotherapy or as sequential therapy after tamoxifen.
The recommended duration of adjuvant AI therapy is usually two to five years. With the recommended treatment period being up to five years in the adjuvant setting, it is important for physicians to understand the clinical pharmacology of some of the commonly used AIs.
Aromatase Inhibitor Development
AIs have been around for over 20 years. Aminoglutethimide was the first AI in general clinical use. Its use was limited by its intermediate efficacy in inhibiting aromatisation and its low specificity, which resulted in significant side effects.12,13 Roglethimide was the second glutethimide derivative, whose use was limited by its low potency and significant side effects.14,15 The second-generation AI fadrozole was then developed and was found to be more specific than aminoglutethimide. It still has significant side effects as it suppresses aldosterone synthesis.16,17 The third-generation AIs anastrozole, letrozole and exemestane have been developed most recently. They are superior in both their high oestrogen biosynthesis suppression and their specificity, resulting in very few side effects.18 Among them, anastrozole and letrozole are non-steroidal AIs, whereas exemestane is steroidal. Anastrozole was the first third-generation AI to be tested in clinical trials in treating metastatic and early-stage hormonereceptor- positive breast cancer in post-menopausal women.
- American Cancer Society, Cancer Facts and Figures, 2009, American Cancer Society, Atlanta, GA, 2009. Available at: www.cancer.org/downloads/STT/500809web.pdf (accessed 9 February 2009).
- Buzdar A, Jonat W, Howell A, et al., Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group, J Clin Oncol, 1996;14:2000–11.
- Buzdar AU, Jonat W, Howell A, et al., Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group, Cancer, 1998;83:1142–52.
- Kaufmann M, Bajetta E, Dirix LY, et al., Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group, J Clin Oncol, 2000;18:1399–411.
- Nabholtz JM, Buzdar A, Pollak M, et al., Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group, J Clin Oncol, 2000;18:3758–67.
- Baum M, Budzar AU, Cuzick J, et al., Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial, Lancet, 2002;359:2131–9.
- Coombes RC, Hall E, Gibson LJ, et al., A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer, N Engl J Med, 2004;350:1081–92.
- Goss PE, Ingle JN, Martino S, et al., A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer, N Engl J Med, 2003;349:1793–802.
- Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, et al., A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer, N Engl J Med, 2005;353:2747–57.
- Boccardo F, Rubagotti A, Puntoni M, et al., Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial, J Clin Oncol, 2005;23:5138–47.
- Winer EP, Hudis C, Burstein HJ, et al., American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004, J Clin Oncol, 2005;23:619–29.
- Wells SA Jr, Santen RJ, Lipton A, et al., Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma, Ann Surg, 1978;187:475–84.
- Lønning PE, Kvinnsland S, Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer, Drugs, 1988;35:685–710.
- MacNeill FA, Jones AL, Jacobs S, et al., The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer, Br J Cancer, 1992;66:692–7.
- Dowsett M, MacNeill F, Mehta A, et al., Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione (‘pyridoglutethimide’) in postmenopausal breast cancer patients, Br J Cancer, 1991;64:887–94.
- Steele RE, Mellor LB, Sawyer WK, et al., In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A, Steroids, 1987;50:147–61.
- Dowsett M, Stein RC, Mehta A, et al., Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients, Clin Endocrinol (Oxf), 1990;32:623–34.
- Buzdar AU, Robertson JF, Eiermann W, et al., An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane, Cancer, 2002;95:2006–16.
- Baum M, Budzar AU, Cuzick J, et al., ATAC Trialists’ Group, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial, Lancet, 2002;359:2131–9.
- Baum M, Buzdar A, Cuzick J, et al., Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with earlystage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses, Cancer, 2003;98:1802–10.
- Center AN, Drug To Prevent Breast Cancer Recurrence Gets FDA Approval, 2002. Available at: www.cancer.org/docroot/ NWS/content/NWS_1_1x_New_Drugs_Or_Old_Standard_ Better_For_Breast_Cancer.asp
- Lønning PE, Geisler J, Dowsett M, Pharmacological and clinical profile of anastrozole, Breast Cancer Res Treat, 1998;49(Suppl. 1):S53–7, discussion S73–7.
- Yates RA, Dowsett M, Fisher GV, et al., Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers, Br J Cancer, 1996;73:543–8.
- Jonat W, Howell A, Blomqvist C, et al., A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer, Eur J Cancer, 1996;32A:404–12.
- Buzdar AU, Jones SE, Vogel CL, et al., A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group, Cancer, 1997;79:730–9.
- Plourde PV, Dyroff M, Dukes M, Arimidex: a potent and selective fourth-generation aromatase inhibitor, Breast Cancer Res Treat, 1994;30:103–11.
- Chu E, DeVita VT, Physicians’ Cancer Chemotherapy Drug Manual, Sudbury, MA, Jones and Bartlett Publishers, 2008.
- AstraZeneca, ARIMIDEX (anastrozole tablets) package insert, 2005.
- Geisler J, King N, Dowsett M, et al., Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer, Br J Cancer, 1996;74:1286–91.
- Grimm SW, Dyroff MC, Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase, Drug Metab Dispos, 1997;25:598–602.
- Dowsett M, Cuzick J, Howell A, et al., Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex and tamoxifen alone or in combination’ (ATAC) trial, Br J Cancer, 2001;85:317–24.
- Bao T, Slater SA, Blackford B, et al., Effect of simvastatin on the pharmacokinetics of anastrozole, J Clin Oncol, 2009;27:15s, abstract 1517.
- Yates RA, Wong J, Seiberling M, et al., The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers, Br J Clin Pharmacol, 2001;51:429–35.
- Repetto L, Vannozzi O, Hazini A, et al., Anastrozole and quinapril can be safely coadministered to elderly women with breast cancer and hypertension: a pharmacokinetic study, Ann Oncol, 2003;14:1587–8.
- Carlini P, Papaldo P, Fabi A, et al., Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?, J Clin Oncol, 2006;24:e60–1.
- Swaisland HC, Ranson M, Smith RP, et al., Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol, Clin Pharmacokinet, 2005;44:1067–81.
- Polychronis A, Sinnett HD, Hadjiminas D, et al., Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermalgrowth- factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial, Lancet Oncol, 2005;6:383–91.